These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 8652250)

  • 1. p53 overexpression as a prognostic factor for advanced stage bladder cancer.
    Kuczyk MA; Bokemeyer C; Serth J; Hervatin C; Oelke M; Höfner K; Tan HK; Jonas U
    Eur J Cancer; 1995 Dec; 31A(13-14):2243-7. PubMed ID: 8652250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder.
    Serth J; Kuczyk MA; Bokemeyer C; Hervatin C; Nafe R; Tan HK; Jonas U
    Br J Cancer; 1995 Jan; 71(1):201-5. PubMed ID: 7819040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
    Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
    J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of the proliferation status (PCNA) and p53 immunohistochemistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder].
    Kuczyk MA; Serth J; Bokemeyer C; Hervatin C; Oelke M; Oelert F; Höfner K; Jonas U
    Urologe A; 1995 Mar; 34(2):146-52. PubMed ID: 7754587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Nagami H; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T; Kawanishi M
    Cancer; 1996 Oct; 78(8):1762-74. PubMed ID: 8859190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity.
    Ogura K; Habuchi T; Yamada H; Ogawa O; Yoshida O
    Int J Urol; 1995 Nov; 2(5):302-8. PubMed ID: 8749948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer.
    Shiina H; Igawa M; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T
    Oncology; 1996; 53(3):233-40. PubMed ID: 8643227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours?
    Plastiras D; Moutzouris G; Barbatis C; Presvelos V; Petrakos M; Theodorou C
    Eur J Surg Oncol; 1999 Feb; 25(1):61-5. PubMed ID: 10188857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy.
    Kuczyk MA; Serth J; Bokemeyer C; Machtens S; Minssen A; Bathke W; Hartmann J; Jonas U
    Eur J Cancer; 1998 Apr; 34(5):679-86. PubMed ID: 9713274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage.
    Skopelitou A; Hadjiyannakis M; Dimopoulos D; Kamina S; Krikoni O; Alexopoulou V; Rigas C; Agnantis NJ
    Eur Urol; 1997; 31(4):464-71. PubMed ID: 9187909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of p53 nuclear overexpression in patients of muscle invasive urinary bladder carcinoma treated with cystectomy.
    Hemal AK; Khaitan A; Dinda AK; Gupta NP; Seth A; Dogra PN; Nabi G
    Urol Int; 2003; 70(1):42-6. PubMed ID: 12566814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of p27Kip1 and p21WAF/Cip protein expression in muscle invasive bladder cancer.
    Kuczyk MA; Machtens S; Bokemeyer C; Hradil K; Macheel I; Jetscho V; Hartmann J; Thon WF; Jonas U; Serth J
    Oncol Rep; 1999; 6(3):687-93. PubMed ID: 10203616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
    Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
    Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.
    Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Lerner SP; Sagalowsky AI; Cote RJ; Lotan Y
    J Urol; 2010 Jan; 183(1):68-75. PubMed ID: 19913255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of p21(waf1/cip1) protein in transitional cell bladder tumours and its prognostic value.
    Lipponen P; Aaltomaa S; Eskelinen M; Ala-Opas M; Kosma VM
    Eur Urol; 1998 Sep; 34(3):237-43. PubMed ID: 9732201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder.
    Thomas DJ; Robinson MC; Charlton R; Wilkinson S; Shenton BK; Neal DE
    Br J Urol; 1994 May; 73(5):533-7. PubMed ID: 8012776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.